Abraham K Brown1, Gera E Nagelhout2, Bas van den Putte3, Marc C Willemsen2, Ute Mons4, Romain Guignard5, Mary E Thompson6. 1. Division of Marketing, Nottingham Business School, Nottingham Trent University, Nottingham, UK. 2. Department of Health Promotion, Maastricht University (CAPHRI), Maastricht, The Netherlands Dutch Alliance for a Smokefree Society, The Hague, The Netherlands. 3. Department of Communication, University of Amsterdam (ASCoR), Amsterdam, The Netherlands Trimbos Institute, Netherlands Institute for Mental Health and Addiction, Utrecht, The Netherlands. 4. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany Unit Cancer Prevention, German Cancer Research Center (DKFZ), Heidelberg, Germany. 5. French Institute for Health Promotion and Health Education (INPES), Saint-Denis, France. 6. Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Canada.
Abstract
OBJECTIVES: To examine if exclusive Roll-Your-Own (RYO) tobacco use relative to factory-made (FM) cigarette use has been rising over time, to determine the extent to which economic motives and perceptions that RYO cigarettes are less harmful act as primary motivations for use, and to examine the association of income and education with the level of RYO tobacco use among smokers in four European countries. METHODS: Data were obtained from the International Tobacco Control (ITC) Europe Surveys, and a cohort sample of 7070 smokers from the Netherlands, Germany, France and UK were interviewed between June 2006 and December 2012. Generalised estimating equations (GEE) were used to assess trends in RYO use, and whether RYO consumption varied by socioeconomic variables. RESULTS: Exclusive RYO use over the study period has increased significantly in the UK from 26.4% in 2007 to 32.7% in 2010 (p<0.001); France from 12.2% in 2006 to 19.1% in 2012 (p<0.001); and Germany from 12.7% in 2007 to 18.6% in 2011 (p=0.031), with increased borderline significantly in the Netherlands (31.7% to 34.3%, p=0.052), from 2008 to 2010. Over three-quarters of users in each of the study countries indicated that lower price was a reason why they smoked RYO. Just over a fourth of smokers in the UK, less than a fifth in France, and around a tenth in Germany and the Netherlands believed that RYO is healthier. Compared with exclusive FM users, exclusive RYO users were more likely to have lower incomes and lower education. CONCLUSIONS: Effective tobacco tax regulation is needed in the European Union and elsewhere to eliminate or reduce the price advantage of RYO tobacco. Additional health messages are also required to correct the misperception that RYO tobacco is healthier than FM cigarettes. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVES: To examine if exclusive Roll-Your-Own (RYO) tobacco use relative to factory-made (FM) cigarette use has been rising over time, to determine the extent to which economic motives and perceptions that RYO cigarettes are less harmful act as primary motivations for use, and to examine the association of income and education with the level of RYOtobacco use among smokers in four European countries. METHODS: Data were obtained from the International Tobacco Control (ITC) Europe Surveys, and a cohort sample of 7070 smokers from the Netherlands, Germany, France and UK were interviewed between June 2006 and December 2012. Generalised estimating equations (GEE) were used to assess trends in RYO use, and whether RYO consumption varied by socioeconomic variables. RESULTS: Exclusive RYO use over the study period has increased significantly in the UK from 26.4% in 2007 to 32.7% in 2010 (p<0.001); France from 12.2% in 2006 to 19.1% in 2012 (p<0.001); and Germany from 12.7% in 2007 to 18.6% in 2011 (p=0.031), with increased borderline significantly in the Netherlands (31.7% to 34.3%, p=0.052), from 2008 to 2010. Over three-quarters of users in each of the study countries indicated that lower price was a reason why they smoked RYO. Just over a fourth of smokers in the UK, less than a fifth in France, and around a tenth in Germany and the Netherlands believed that RYO is healthier. Compared with exclusive FM users, exclusive RYO users were more likely to have lower incomes and lower education. CONCLUSIONS: Effective tobacco tax regulation is needed in the European Union and elsewhere to eliminate or reduce the price advantage of RYOtobacco. Additional health messages are also required to correct the misperception that RYOtobacco is healthier than FM cigarettes. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: M E Thompson; G T Fong; D Hammond; C Boudreau; P Driezen; A Hyland; R Borland; K M Cummings; G B Hastings; M Siahpush; A M Mackintosh; F L Laux Journal: Tob Control Date: 2006-06 Impact factor: 7.552
Authors: G T Fong; K M Cummings; R Borland; G Hastings; A Hyland; G A Giovino; D Hammond; M E Thompson Journal: Tob Control Date: 2006-06 Impact factor: 7.552
Authors: Richard J O'Connor; Ann McNeill; Ron Borland; David Hammond; Bill King; Christian Boudreau; K Michael Cummings Journal: Nicotine Tob Res Date: 2007-10 Impact factor: 4.244
Authors: Mohammad Siahpush; Melanie A Wakefield; Matt J Spittal; Sarah J Durkin; Michelle M Scollo Journal: Am J Prev Med Date: 2009-02-06 Impact factor: 5.043
Authors: Gera E Nagelhout; Marc C Willemsen; Mary E Thompson; Geoffrey T Fong; Bas van den Putte; Hein de Vries Journal: BMC Public Health Date: 2010-06-18 Impact factor: 3.295
Authors: Sarah Joseph; Nicolle M Krebs; Junjia Zhu; Yijin Wert; Reema Goel; Samantha M Reilly; Dongxiao Sun; John P Richie; Ivan Nikiforov; Pramil Cheriyath; Joshua E Muscat Journal: Drug Alcohol Depend Date: 2018-04-07 Impact factor: 4.492
Authors: Valentina Minardi; Gianluigi Ferrante; Paolo D'Argenio; Maria Masocco; Lorenzo Spizzichino; Carla Bietta; Benedetta Contoli; Silvano Gallus Journal: Int J Public Health Date: 2019-01-25 Impact factor: 3.380
Authors: Filippos T Filippidis; Pete Driezen; Christina N Kyriakos; Paraskevi Katsaounou; Ioanna Petroulia; Charis Girvalaki; Marcela Fu; Esteve Fernández; Ute Mons; Antigona C Trofor; Tibor Demjén; Krzysztof Przewoźniak; Witold A Zatoński; Geoffrey T Fong; Yannis Tountas; Constantine I Vardavas Journal: Eur J Public Health Date: 2020-07-01 Impact factor: 3.367
Authors: J Robert Branston; Ann McNeill; Anna B Gilmore; Rosemary Hiscock; Timea R Partos Journal: Drug Alcohol Depend Date: 2018-10-06 Impact factor: 4.492
Authors: Constantine I Vardavas; Christina N Kyriakos; Pete Driezen; Charis Girvalaki; Katerina Nikitara; Filippos T Filippidis; Esteve Fernández; Ute Mons; Krzysztof Przewoźniak; Antigona C Trofor; Tibor Demjén; Paraskevi A Katsaounou; Witold Zatoński; Marc Willemsen; Geoffrey T Fong Journal: Eur J Public Health Date: 2020-07-01 Impact factor: 3.367
Authors: Jeroen Bommelé; Gera E Nagelhout; Marloes Kleinjan; Tim M Schoenmakers; Marc C Willemsen; Dike van de Mheen Journal: BMC Public Health Date: 2016-08-09 Impact factor: 3.295
Authors: Rosemary Hiscock; J Robert Branston; Ann McNeill; Sara C Hitchman; Timea R Partos; Anna B Gilmore Journal: Tob Control Date: 2017-10-09 Impact factor: 7.552
Authors: Filippos T Filippidis; Anthony A Laverty; Thomas Hone; Jasper V Been; Christopher Millett Journal: JAMA Pediatr Date: 2017-11-01 Impact factor: 16.193